Compare Commvault Systems Inc (CVLT) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Commvault Systems Inc vs IDEXX Laboratories, Inc. — how do they compare? Commvault Systems Inc trades at $141.97 (market cap $5.78B), while IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 8× Commvault Systems Inc's market cap, and Commvault Systems Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| CVLT | IDXX | |
|---|---|---|
Market Cap | $5.78B | $46.22B |
Sector | Technology | Health |
52-Week High | $195.41 | $766.68 |
52-Week Low | $75.18 | $526.44 |
Enterprise Value | $5.76B | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Commvault Systems (CVLT) trades at $141.74, up 1.66% today, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.42 per share, beating estimates, and has a consensus analyst price target of $172.40. Revenue growth is robust, with 2026 projections at $1.2 billion, though net income margin is expected to compress. Recent news includes a shareholder investigation and positive developments in threat scan integration.
The outlook is positive given earnings beats and subscription growth, but high valuation ratios (P/E of 89.35) and margin pressure pose risks. Investor sentiment is buoyed by analyst buy ratings (54.55%), though legal scrutiny and competitive threats require monitoring for sustained upside.
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Commvault Systems Inc
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
